Benign prostatic hyperplasia (BPH) is clinically relevant when it causes lower urinary tract symptoms (LUTS), reduces quality of life, or increases the risk of acute urinary retention (AUR) or surgery. Contemporary European guidance recommends alpha-1 blockers for rapid symptom relief and 5-alpha-reductase inhibitors (5-ARIs) for men with moderate-to-severe LUTS who are at increased risk of progression, especially when prostate volume is greater than 40 mL. The American Urological Association similarly recommends 5-ARI therapy only when enlargement is demonstrated by imaging volume, palpable enlargement, or prostate-specific antigen (PSA) as a size proxy [1, 2]. This volume-based approach matters because 5-ARIs reduce the static component of obstruction, whereas alpha-blockers relax smooth muscle at the prostate and bladder neck.

Dutasteride inhibits both type 1 and type 2 5-alpha-reductase isoenzymes, thereby suppressing the conversion of testosterone to dihydrotestosterone more broadly than finasteride. Australian product information for both dutasteride monotherapy and dutasteride–tamsulosin combination therapy emphasizes that prostate-cancer risk assessment should occur before treatment and during follow-up. Mean PSA falls by approximately 50% after 6 months, and any confirmed rise from the lowest on-treatment PSA should be evaluated even if the absolute value remains within the usual untreated reference range [3, 4].

The strongest trial evidence supports long-term treatment in men with enlarged prostates and higher risk of BPH progression. The Medical Therapy of Prostatic Symptoms (MTOPS) trial showed that finasteride-based combination therapy reduced overall clinical BPH progression more than either monotherapy. The dutasteride–tamsulosin CombAT trial showed durable reductions in AUR and BPH-related surgery over 4 years in men enrolled with a prostate volume of at least 30 cm³ and a PSA of 1.5–10 ng/mL [5, 6].

The remaining concern is prostate-cancer detection. The US Food and Drug Administration (FDA) warning followed the Prostate Cancer Prevention Trial (PCPT) and Reduction by Dutasteride of Prostate Cancer Events (REDUCE) trial. These trials reduced overall prostate-cancer detection but reported a higher proportion or numerical imbalance of high-grade cancers in treated groups [7–9]. In other words, these trials established increased risk of high-grade cancer due to delayed prostate cancer detection. Later evidence shifted interpretation toward delayed detection and PSA-monitoring effects rather than a clear lethal-cancer effect. Bias-adjusted PCPT modeling, extended PCPT follow-up, a mortality-focused systematic review, and recent Swedish and Ontario cohorts did not show increased prostate cancer-specific mortality [10–14]. In contrast, a Veterans Affairs cohort study showed delayed diagnosis and worse outcomes among 5-ARI users when PSA suppression was not managed correctly, showing that monitoring affects safety [15].

This narrative review used current urology guidelines, regulatory product information, pivotal randomized controlled trials, prostate-cancer prevention trials, systematic reviews, and population-based cohorts. We prioritized primary sources and authoritative guidelines or regulatory documents. Digital object identifier (DOI)-bearing references were checked against publisher, PubMed, or guideline metadata. Non-journal sources were retained only when they were primary or authoritative. Because the literature includes guidelines, trials, observational cohorts, and regulatory documents, a narrative approach was used rather than a pooled meta-analysis. The aim is to provide a practical academic review for clinicians managing BPH/LUTS with dutasteride-based therapy.

5-ARI therapy is a gland-indexed treatment. In men with large prostates, androgen-driven epithelial and stromal growth contributes to obstruction and future clinical risk. European Association of Urology (EAU) guidance reports that 5-ARIs reduce prostate size by approximately 18–28%, lower circulating PSA by approximately 50% after 6–12 months, improve International Prostate Symptom Score (IPSS) by approximately 15–30%, and increase peak urinary flow by approximately 1.5–2.0 mL/s after 2 to 4 years in men with LUTS due to prostatic enlargement [1]. It also notes that finasteride is not more effective than placebo when prostate volume is below 40 mL, while dutasteride may still help some men with volumes of 30–40 mL. These data support a practical size threshold rather than an absolute anatomical rule [1].

When imaging is unavailable, PSA can be used cautiously as a surrogate for volume, but not as a cancer-exclusion tool. The EAU diagnostic guidance reports that PSA has good predictive value for prostate volume, that PSA greater than 1.5 ng/mL predicts prostate volume above 30 mL with a positive predictive value of 78%, and that age-specific PSA cut-points can help identify glands larger than 40 mL [1]. AUA guidance similarly supports 5-ARI use when prostate enlargement is demonstrated by volume criteria, palpable enlargement, or PSA-based proxies [2]. Thus, the statement that a prostate is “not large enough” for dutasteride is a treatment-selection statement. It means the expected benefit is lower, while adverse effects and the complexity of PSA interpretation remain.

The MTOPS trial separated rapid symptom control from prevention of clinical progression. Doxazosin and finasteride each reduced clinical progression compared with placebo, but combination therapy produced the greatest risk reduction. Finasteride-containing arms were particularly important in reducing AUR and invasive therapy, supporting the role of 5-ARI treatment as disease-modifying rather than simple symptom palliation [5].

CombAT applied this principle to dutasteride plus tamsulosin. The trial enrolled men aged at least 50 years with moderate-to-severe symptoms, prostate volume at least 30 cm³, and PSA 1.5–10 ng/mL. Over 4 years, combination therapy produced stronger symptoms and progression outcomes than either component alone in this enlarged-prostate population [6]. EAU synthesis reports relative reductions versus tamsulosin of approximately 68% for AUR, 71% for BPH-related surgery, and 41% for symptom deterioration [1]. These results support fixed-dose dutasteride–tamsulosin when a man needs both early relief and long-term risk reduction, but they do not justify routine use in men with small prostates and minimal expected benefit.

The PCPT and REDUCE trials established the concern that 5-ARI therapy may increase the risk of delayed diagnosis leading to high-grade cancer detection. PCPT found fewer prostate cancers overall with finasteride but a greater proportion of detected Gleason 7–10 cancers [8]. REDUCE found fewer biopsy-detected prostate cancers with dutasteride but reported a numerical imbalance in Gleason 8–10 cancers, especially late in follow-up [9]. Regulatory warnings advise that 5-ARIs are not approved for prostate cancer prevention and may increase the chance of delayed diagnosis leading to high-grade disease [7].

Several factors make these trial findings difficult to interpret. 5-ARIs shrink the prostate, increase biopsy sampling density, change PSA performance, and may influence histological grading. Bias-adjusted PCPT modeling concluded that the apparent excess of high-grade cancer was unlikely to represent a true increase in aggressive tumors [10]. Long-term PCPT follow-up found no significant difference in overall survival between finasteride and placebo [11]. Mortality-focused evidence is also reassuring: a systematic review and meta-analysis of more than 3 million patients found no significant association between 5-ARI use and prostate-cancer mortality, and large Swedish and Ontario cohorts did not show increased prostate cancer-specific mortality after adjustment [12–14].

Nevertheless, reassurance depends on surveillance. Sarkar et al found that 5-ARI use in a Veterans Affairs cohort was associated with longer time from PSA elevation to biopsy and worse prostate-cancer outcomes, a pattern consistent with under-recognition of PSA suppression rather than drug-driven carcinogenesis [15]. In practice, the modifiable hazard is misinterpretation of a suppressed PSA.

PSA monitoring must be planned before dutasteride is prescribed. Product information for dutasteride monotherapy and dutasteride–tamsulosin combination therapy instructs clinicians to perform digital rectal examination (DRE) and appropriate cancer evaluation before therapy, establish a new PSA baseline after 6 months, monitor regularly, and evaluate any confirmed increase from the lowest on-treatment PSA [3, 4]. The traditional doubling rule compares a stabilized on-treatment PSA with untreated reference ranges by multiplying the measured value by approximately 2, but this is only a simplification. Expert PSA reviews recommend interpreting PSA in relation to the individual nadir and clinical context [16]. The REDUCE trial supports the usefulness of PSA rise as a cancer marker during dutasteride treatment and shows that increases after the 6-month nadir are particularly informative for clinically relevant or high-grade cancer [17, 18].

A practical approach is to document the pre-treatment PSA and DRE, record prostate volume or a volume proxy, repeat PSA at about 6 months, and label the result as the on-treatment baseline. Thereafter, any confirmed rise should prompt a review of adherence, an assessment for transient causes such as infection or instrumentation, and a referral for prostate-cancer risk assessment when unexplained. The PSA value should not be dismissed simply because it remains below a conventional threshold for untreated men.

Multiparametric MRI provides an additional diagnostic safeguard but does not replace serial PSA measurements. The EAU prostate-cancer guidance recommends MRI before biopsy in men with suspected organ-confined prostate cancer, adherence to Prostate Imaging Reporting and Data System (PI-RADS) acquisition and reporting standards, targeted biopsy where MRI shows a suspicious lesion and combined targeted plus perilesional sampling when PI-RADS is 4 or higher [19]. PSA density and family history refine decisions when MRI is negative or indeterminate. For 5-ARI users, MRI-first pathways are most effective when PSA changes are recognized promptly. Although reports of PSA–positron emission tomography (PET) discordance come from recurrent prostate cancer rather than BPH screening, they reinforce the broader diagnostic principle that imaging should complement, rather than replace, longitudinal PSA interpretation [20].

The benefit–risk discussion should include sexual, cardiovascular, mood, and metabolic considerations. EAU guidance and trial experience identify reduced libido, erectile dysfunction, and ejaculatory dysfunction as clinically important adverse effects, especially when dutasteride is combined with tamsulosin [1, 6]. Australian product information describes a cardiac-failure composite imbalance in some combination-therapy datasets while noting uncertainty about causality [3, 4]. These signals do not preclude treatment, but they make careful patient selection important, especially for men with small prostates, minimal expected benefit, or significant cardiovascular comorbidity.

Mood-related vigilance is also warranted. A Swedish registry study in JAMA Network Open found associations between 5-ARI exposure and depression; dementia associations diminished over time, and suicide associations were not supported in that analysis [21]. The European Medicines Agency subsequently confirmed suicidal ideation as an adverse effect of finasteride tablets and stated that a direct link could not be established for dutasteride, although dutasteride product information cautions about mood changes [22]. Clinicians should therefore ask about baseline mood symptoms and advise patients to report depressed mood or suicidal thoughts promptly.

A BMJ population-based study reported a higher risk of incident type 2 diabetes in men receiving 5-ARIs compared with tamsulosin, whereas a newer active-comparator, new-user cohort from Korea found minimal overall effects, with no significant increase in the risk of hyperglycemia for dutasteride compared with tamsulosin [23, 24]. For men with diabetes or high cardiometabolic risk, these data support monitoring rather than avoidance.

Table 1 [1–6, 15, 21–24] summarizes treatment selection by clinical phenotype. Table 2 [3, 4, 16–19] provides a surveillance framework for the central safety problem: avoiding delayed prostate-cancer detection while preserving the benefits of dutasteride-based therapy.

Click to view

Table 1. Volume-Selected Treatment Framework for LUTS/BPH When Considering Dutasteride-Based Therapy

Click to view

Table 2. PSA and Prostate-Cancer Surveillance Pathway for Men Receiving Dutasteride or Dutasteride–Tamsulosin

The evidence base supports a balanced message: the evidence for dutasteride use is strongest when the prostate is enlarged, symptoms are bothersome, and prevention of AUR or surgery is clinically meaningful [1–6]. In the setting of a small prostate, the benefit is low in light of sexual adverse effects, mood and metabolic risks, and the complexity of PSA interpretation [1, 21–24]. Conversely, men with enlarged glands and high progression risk should not be denied effective therapy. The key safeguard is a system that makes PSA suppression visible to every clinician who interprets the result.

Documentation should therefore accompany prescribing. Records should include the baseline PSA, DRE result, prostate volume or PSA-volume proxy, indication for 5-ARI therapy, planned 6-month PSA re-baseline, and the instruction that any confirmed rise from nadir requires evaluation. A low raw PSA during therapy should be interpreted as an adjusted and kinetic result, not as a simple cancer-negative result. Electronic medical records and referral letters should state “on dutasteride/5-ARI” beside PSA values. Without this, the same medication that improves BPH outcomes can delay cancer diagnosis.

This review is narrative and does not provide a formal pooled estimate of benefit or harm. The thresholds discussed here are based on guideline recommendations, trial inclusion criteria, and volume-surrogate analyses, rather than a single universally validated cut-point. In addition, prostate volume, PSA, baseline cancer risk, access to MRI, and clinician follow-up behavior vary substantially across health systems. Mortality reassurance is strongest in settings where PSA testing is recorded and acted on; it should not be extrapolated to situations in which PSA suppression is ignored, or referral pathways are inaccessible [12–15]. The evidence for mood and metabolic outcomes is also largely observational and vulnerable to residual confounding, although it is clinically relevant enough to inform counseling and follow-up [21–24]. These limitations support careful documentation and shared decision-making, rather than overprescribing 5-ARIs or avoiding them in men likely to benefit.

Dutasteride and dutasteride–tamsulosin remain evidence-based options for men with LUTS/BPH who have demonstrable prostatic enlargement and meaningful risk of AUR or surgery. Prostate size thresholds should be viewed as benefit–risk thresholds: larger glands are more likely to benefit, while smaller glands have less expected therapeutic gain but still require adverse-effect counseling and PSA reinterpretation. Current evidence does not show a clear increase in prostate cancer-specific mortality in adequately monitored 5-ARI users. Safe practice requires baseline assessment, 6-month PSA re-baselining, regular monitoring, prompt evaluation of any confirmed rise in PSA from nadir, and MRI-first diagnostic escalation when clinically indicated.

1. Gravas S, Cornu JN, Gacci M, Gratzke C, Herrmann TRW, Mamoulakis C, et al. EAU guidelines on the management of non-neurogenic male lower urinary tract symptoms (LUTS), including benign prostatic obstruction (BPO). Arnhem: European Association of Urology; 2025. Available from: https://uroweb.org/guidelines/management-of-non-neurogenic-male-luts. Accessed Apr 30, 2026.
2. Sandhu JS, Bixler BR, Dahm P, Goueli R, Kirkby E, Stoffel JT, et al. Management of Lower Urinary Tract Symptoms Attributed to Benign Prostatic Hyperplasia (BPH): AUA Guideline Amendment 2023. J Urol. 2024;211(1):11-19.
   doi
3. GlaxoSmithKline Australia Pty Ltd. Dutasteride 0.5 mg soft capsules: Australian product information. Available from: https://au.gsk.com/media/aeynzvhc/avodart_pi_012_approved.pdf. Australian product information; 2024. Accessed Apr 30, 2026.
4. GlaxoSmithKline Australia Pty Ltd. Dutasteride 0.5 mg/tamsulosin hydrochloride 0.4 mg modified-release capsules: Australian product information. Available from: https://au.gsk.com/media/nn3pnqrz/duodart_pi_au.pdf. Australian product information; 2024. Accessed Apr 30, 2026.
5. McConnell JD, Roehrborn CG, Bautista OM, Andriole GL, Jr., Dixon CM, Kusek JW, Lepor H, et al. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med. 2003;349(25):2387-2398.
   doi pubmed
6. Roehrborn CG, Siami P, Barkin J, Damiao R, Major-Walker K, Nandy I, Morrill BB, et al. The effects of combination therapy with dutasteride and tamsulosin on clinical outcomes in men with symptomatic benign prostatic hyperplasia: 4-year results from the CombAT study. Eur Urol. 2010;57(1):123-131.
   doi pubmed
7. U.S. Food and Drug Administration. Dutasteride capsules prescribing information. Revised 2020. U.S. FDA Drugs@FDA database. Available from: https://nctr-crs.fda.gov/fdalabel/services/spl/set-ids/2ee1eef5-8ec7-46c1-b4fa-13184915448f/spl-doc?hl=dutasteride. Accessed Apr 30, 2026.
8. Thompson IM, Goodman PJ, Tangen CM, Lucia MS, Miller GJ, Ford LG, Lieber MM, et al. The influence of finasteride on the development of prostate cancer. N Engl J Med. 2003;349(3):215-224.
   doi pubmed
9. Andriole GL, Bostwick DG, Brawley OW, Gomella LG, Marberger M, Montorsi F, Pettaway CA, et al. Effect of dutasteride on the risk of prostate cancer. N Engl J Med. 2010;362(13):1192-1202.
   doi pubmed
10. Redman MW, Tangen CM, Goodman PJ, Lucia MS, Coltman CA, Jr., Thompson IM. Finasteride does not increase the risk of high-grade prostate cancer: a bias-adjusted modeling approach. Cancer Prev Res (Phila). 2008;1(3):174-181.
    doi pubmed
11. Thompson IM, Jr., Tangen CM, Goodman PJ. Re: Long-term survival of participants in the Prostate Cancer Prevention Trial. Asian J Androl. 2014;16(3):414.
    doi pubmed
12. Baboudjian M, Gondran-Tellier B, Dariane C, Fiard G, Fromont G, Roupret M, Ploussard G. Association between 5alpha-reductase inhibitors and prostate cancer mortality: a systematic review and meta-analysis. JAMA Oncol. 2023;9(6):847-850.
    doi pubmed
13. Bjornebo L, Nordstrom T, Discacciati A, Palsdottir T, Aly M, Gronberg H, Eklund M, et al. Association of 5alpha-Reductase Inhibitors With Prostate Cancer Mortality. JAMA Oncol. 2022;8(7):1019-1026.
    doi pubmed
14. Hamilton RJ, Chavarriaga J, Khurram N, Lau C, Luo J, Liu N, Komisarenko M, et al. 5-alpha reductase inhibitors and prostate cancer mortality. JAMA Netw Open. 2024;7(8):e2430223.
    doi pubmed
15. Sarkar RR, Parsons JK, Bryant AK, Ryan ST, Kader AK, McKay RR, D'Amico AV, et al. Association of treatment with 5alpha-reductase inhibitors with time to diagnosis and mortality in prostate cancer. JAMA Intern Med. 2019;179(6):812-819.
    doi pubmed
16. Marks LS, Andriole GL, Fitzpatrick JM, Schulman CC, Roehrborn CG. The interpretation of serum prostate specific antigen in men receiving 5alpha-reductase inhibitors: a review and clinical recommendations. J Urol. 2006;176(3):868-874.
    doi pubmed
17. Marberger M, Freedland SJ, Andriole GL, Emberton M, Pettaway C, Montorsi F, Teloken C, et al. Usefulness of prostate-specific antigen (PSA) rise as a marker of prostate cancer in men treated with dutasteride: lessons from the REDUCE study. BJU Int. 2012;109(8):1162-1169.
    doi pubmed
18. Andriole GL, Bostwick D, Brawley OW, Gomella L, Marberger M, Montorsi F, Pettaway C, et al. The effect of dutasteride on the usefulness of prostate specific antigen for the diagnosis of high grade and clinically relevant prostate cancer in men with a previous negative biopsy: results from the REDUCE study. J Urol. 2011;185(1):126-131.
    doi pubmed
19. European Association of Urology. EAU guidelines on prostate cancer: diagnostic evaluation. Arnhem: European Association of Urology; 2026. Available from: https://uroweb.org/guidelines/prostate-cancer/chapter/diagnostic-evaluation. Accessed Apr 30, 2026.
20. Lim ECN, Lim CED. Discordance between prostate-specific antigen and positron emission tomography imaging in recurrent prostate cancer. World J Nephrol Urol. 2025;14(2):27-34.
    doi
21. Garcia-Argibay M, Hiyoshi A, Fall K, Montgomery S. Association of 5alpha-Reductase Inhibitors With Dementia, Depression, and Suicide. JAMA Netw Open. 2022;5(12):e2248135.
    doi pubmed
22. European Medicines Agency. Measures to minimise risk of suicidal thoughts with finasteride and dutasteride medicines. Published 8 May 2025. Available from: https://www.ema.europa.eu/en/news/measures-minimise-risk-suicidal-thoughts-finasteride-dutasteride-medicines. Accessed Apr 30, 2026.
23. Wei L, Lai EC, Kao-Yang YH, Walker BR, MacDonald TM, Andrew R. Incidence of type 2 diabetes mellitus in men receiving steroid 5alpha-reductase inhibitors: population based cohort study. BMJ. 2019;365:l1204.
    doi pubmed
24. Nguyen M-H, Cho J, Ko J. Risk of type 2 diabetes mellitus in new users of 5-alpha reductase inhibitors compared with tamsulosin among patients with benign prostatic hyperplasia. Yonsei Med J. 2026;67(4):368-376.
    doi